Property:Outcome name
This is a property of type Text.
The allowed values for this property are:
- Additional medication
- Anorexia/Cachexia
- Antibodies
- Anxiety
- Appetite
- Arterial inflow
- BMD (Bone Mineral Density)
- Body composition
- Carnitine level
- Carotenoid concentration
- Cerebral oedema
- CINV (Chemotherapy-Induced Nausea and Vomiting)
- Cognitive functioning
- Cognitive impairment
- Depression
- Dermatitis
- DFS (Disease-Free Survival)
- Diarrhoe
- Distress
- Dysgeusia
- Ejection fraction
- Erectile dysfunction
- Erythema
- Esophagitis
- Fatigue
- Fever
- Fibrosis
- Folic acid level
- Functionality
- Haematological indices
- Haematological toxicity
- Hand-foot syndrome
- Hand grip strength
- Hormone level
- Incidence of acute GVHD (Graft-Versus-Host Disease)
- Infection
- Interaction with cancer treatment
- Ileus (intestinal obstruction)
- Laboratory parameters
- Length of hospital stay
- Lymphedema
- Menopausal symptoms
- Mental status/ function
- Mood/Affect
- Mortality rate
- Mucositis
- Musculoskeletal symptoms
- Nausea
- Nausea and Vomiting
- Nerve conduction velocity
- Neurotoxicity
- Neutropenia
- Non-haematological indices
- Nutrition status
- Objective signs and subjective symptoms
- Oral ulcus
- OS (Overall Survival)
- Ototoxicity
- Pain
- PD (Pharmacodynamics)
- Performance Status
- Peripheral neuropathy
- PFS (Progression-Free Survival)
- Pharyngitis
- Physical functioning
- PK (Pharmacokinetics)
- Postoperative morbidity/ complications
- PSA level (Prostate-Specific Antigen)
- Quality of life
- Recurrence rate
- REE (Resting Energy Expenditure)
- Relaxation
- RFS (Recurrence-Free Survival)
- Salivary gland function
- Seroconversion
- Selenium level
- Sleep
- Stomatitis
- Stress
- Symptom load
- Taste alteration
- Tea polyphenol uptake
- Thromboembolic event rates
- Toxicity
- Treatment interruption
- Tumor progression
- Tumor response
- Vaginal atrophy
- Vitamin A level
- Vitamin B6 level
- Vitamin B12 level
- Vitamin B17 level
- Vitamin C level
- Vitamin D level
- Vitamin E level
- Vomiting
- Weight
- Well-being
- Wound healing
- Wound odour
- Xerostomia
- Zinc level
- Unspecified effects
- NI
- ?
M
Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology +
Quality of life +
Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology +
Toxicity +
Muecke et al. (2013): Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology-a subgroup analysis of a multicenter, phase III trial +
Toxicity +
Muecke et al. (2014): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization +
DFS (Disease-Free Survival) +
Muecke et al. (2014): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization +
OS (Overall Survival) +
N
Najafizade et al. (2013): Preventive effects of zinc sulfate on taste alterations in patients under irradiation for head and neck cancers: A randomized placebo-controlled trial +
Taste alteration +
Nasser et al. (2017): Vitamin D ointment for prevention of radiation dermatitis in breast cancer patients +
Dermatitis +
Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group +
Recurrence rate +
Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group +
DFS (Disease-Free Survival) +
Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group +
Tumor response +
Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group +
OS (Overall Survival) +
Ng et al. (2019): Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial +
Vitamin D level +
Ng et al. (2019): Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial +
PFS (Progression-Free Survival) +
Ng et al. (2019): Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial +
Tumor response +
Ng et al. (2019): Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial +
OS (Overall Survival) +
Nguyen et al. (2012): Randomized, Double-Blind, Placebo-Controlled Trial of Polyphenon E in Prostate Cancer Patients before Prostatectomy: Evaluation of Potential Chemopreventive Activities +
PSA level (Prostate-Specific Antigen) +
Niravath et al. (2019): Randomized controlled trial of high‐dose versus standard‐dose vitamin D3 for prevention of aromatase inhibitor‐induced arthralgia +
Interaction with cancer treatment +
Niravath et al. (2019): Randomized controlled trial of high‐dose versus standard‐dose vitamin D3 for prevention of aromatase inhibitor‐induced arthralgia +
Vitamin D level +
Showing 1 related entity.
{ "type": "PROPERTY_CONSTRAINT_SCHEMA", "constraints": { "type_constraint": "_txt", "allowed_values": [ "Anorexia/Cachexia", "Anxiety", "Appetite", "Cerebral oedema", "Cognitive functioning", "Cognitive impairment", "Depression", "Dermatitis", "Distress", "Dysgeusia", "Ejection fraction", "Erectile dysfunction", "Fatigue", "Haematological toxicity", "Hand-foot syndrome", "Ileus (intestinal obstruction)", "Lymphedema", "Menopausal symptoms", "Mood/Affect", "Mucositis", "Nausea", "Nausea and Vomiting", "Neutropenia", "Ototoxicity", "Pain", "Quality of life", "Recurrence rate", "Relaxation", "Stress", "Toxicity", "Vaginal atrophy", "Vomiting", "Weight", "Well-being", "Wound healing", "Xerostomia", "?", "NI", "Esophagitis", "Seroconversion", "Antibodies", "Carnitine level", "Folic acid level", "Haematological indices", "Incidence of acute GVHD (Graft-Versus-Host Disease)", "Length of hospital stay", "Mortality rate", "Non-haematological indices", "Performance Status", "Selenium level", "Tumor response", "Vitamin A level", "Vitamin B6 level", "Vitamin B12 level", "Vitamin B17 level", "Vitamin C level", "Vitamin D level", "Vitamin E level", "Zinc level", "OS (Overall Survival)", "Body composition", "Diarrhoe", "Nutrition status", "PSA level (Prostate-Specific Antigen)", "Taste alteration", "Tumor progression", "DFS (Disease-Free Survival)", "PFS (Progression-Free Survival)", "RFS (Recurrence-Free Survival)", "Carotenoid concentration", "Pharyngitis", "CINV (Chemotherapy-Induced Nausea and Vomiting)", "Fibrosis", "Functionality", "Hand grip strength", "Hormone level", "Musculoskeletal symptoms", "Objective signs and subjective symptoms", "Salivary gland function", "Thromboembolic event rates", "Wound odour", "BMD (Bone Mineral Density)", "PD (Pharmacodynamics)", "Sleep", "Tea polyphenol uptake", "Unspecified effects", "Peripheral neuropathy", "PK (Pharmacokinetics)", "Arterial inflow", "Erythema", "Laboratory parameters", "Mental status/ function", "Neurotoxicity", "Oral ulcus", "Physical functioning", "Additional medication", "Interaction with cancer treatment", "REE (Resting Energy Expenditure)", "Treatment interruption", "Fever", "Infection", "Nerve conduction velocity", "Postoperative morbidity/ complications", "Stomatitis", "Symptom load" ] } }